AlzeCure Pharma has shared exciting news: they’ve received the first part of a EUR 2.5 million grant from the European Innovation Council (EIC). This money will help them conduct a phase 2a clinical study of their new drug, ACD856, which is being developed to treat Alzheimer’s disease. The EIC Accelerator grant will allow AlzeCure to move forward with trials in patients. ACD856 is designed to boost learning and memory and potentially slow down the progression of Alzheimer’s. This drug is a Trk-PAM, a new type of medication that enhances important brain signals, BDNF and NGF, which are linked to thinking and memory in conditions like Alzheimer’s, sleep disorders, brain injuries, and Parkinson’s disease. Earlier studies have shown that ACD856 is safe, can enter the brain effectively, and activates pathways important for thinking and mood. Preclinical data also suggests it may improve brain cell communication, learning, memory, and offer protective and anti-inflammatory benefits, including better energy production in brain cells. Johan Sandin, Chief Scientific Officer at AlzeCure Pharma, said: “ACD856 works in a unique way and could improve learning and memory, as well as potentially altering the course of the disease. This is important for patients with Alzheimer’s and other brain conditions. The support from the EIC is a strong vote of confidence in our project and its innovative potential. This grant will help us continue our clinical studies and speed up the development of this much-needed treatment for Alzheimer’s patients.” Martin Jönsson, CEO of AlzeCure Pharma, added: “We’re very happy to receive this grant from the EIC, which validates our work and is crucial for bringing this new treatment to patients. Alzheimer’s is the most common form of dementia and affects about 55 million people worldwide, with numbers expected to triple in the next 30 years. The disease is a huge burden on patients, their families, and society, and there’s a great need for new, effective treatments. With this grant, AlzeCure Pharma is taking an important step towards offering a new treatment option for this serious disease.”